Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: Phase 3 STOP-HS1 and STOP-HS2 Trials of Povorcitinib for Hidradenitis Suppurativa: Randomized, Double-Blind, Placebo-Controlled Studies

  • By

  • Martina L. Porter

  • Antonio Martorell

  • Christopher J. Sayed

  • Falk G. Bechara

  • Hadar Lev-Tov

  • Jennifer L. Hsiao

  • John W. Frew

  • Ziad Reguiaï

  • Melinda J. Gooderham

  • Noah Goldfarb

  • Hessel H. van der Zee

  • Veronique del Marmol

  • Angelo V. Marzano

  • Benjamin D. Ehst

  • Lindsay S. Ackerman

  • Koremasa Hayama

  • Chenwei Tian

  • Jennifer Kelley

  • Huiling Zhen

  • Joslyn S. Kirby

  • Kurt Brown

  • Leandro L. Santos

  • Christos C. Zouboulis

  • October 21, 2026

Share

Original Source(s)

Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

  • by Martina L. Porter, Antonio Martorell, Christopher J. Sayed, Falk G. Bechara, Hadar Lev-Tov, Jennifer L. Hsiao, John W. Frew, Ziad Reguiaï, Melinda J. Gooderham, Noah Goldfarb, Hessel H. van der Zee, Veronique del Marmol, Angelo V. Marzano, Benjamin D. Ehst, Lindsay S. Ackerman, Koremasa Hayama, Chenwei Tian, Jennifer Kelley, Huiling Zhen, Joslyn S. Kirby, Kurt Brown, Leandro L. Santos, Christos C. Zouboulis

  • October 21, 2026

Related Content

Cancer Risk Assessment in Individuals with Hidradenitis Suppurativa: A Comprehensive Review and Meta-Analysis

Financial Impact of Hidradenitis Suppurativa in Spain

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness